Novo Nordisk A/S (NOVO-B) - Stock Price & Dividends

Exchange: Copenhagen Exchange • Country: Denmark • Currency: DKK • Type: Common Stock • ISIN: DK0062498333

Insulin, Diabetes, Obesity, Hormone, Growth

Novo Nordisk A/S is a global healthcare company that develops, manufactures, and distributes pharmaceutical products to improve the lives of people worldwide. With a strong presence in Europe, the Middle East, Africa, Asia, and North America, the company is committed to discovering and delivering innovative treatments for various diseases and conditions.

The company operates two main business segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment focuses on developing treatments for diabetes, obesity, cardiovascular diseases, and emerging therapy areas. On the other hand, the Rare Disease segment concentrates on creating treatments for rare blood disorders, rare endocrine disorders, and hormone replacement therapy.

Novo Nordisk A/S is renowned for its insulin products, including insulin pens, growth hormone pens, and injection needles. The company has also developed innovative smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application that helps patients manage their diabetes more effectively.

Collaboration is an essential part of Novo Nordisk A/S's business strategy. The company has partnered with Aspen Pharmaceuticals to produce insulin products, ensuring a steady supply of high-quality medicines to patients who need them.

With a rich history dating back to 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark. Today, the company is a global leader in the pharmaceutical industry, driven by its commitment to improving human health and quality of life.

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for Novo Nordisk A/S (NOVO-B) - Stock Price & Dividends

Overall Trend and Yearly Seasonality

Drawdown / Underwater Chart for Novo Nordisk A/S (NOVO-B) - Stock Price & Dividends

NOVO-B Stock Overview

Market Cap in USD 626,587m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception

NOVO-B Stock Ratings

Growth 5y 96.8
Fundamental 68.8
Dividend 8.49
Rel. Performance vs Sector 5.69
Analysts -
Fair Price Momentum 1322.77 DKK
Fair Price DCF 407.99 DKK

NOVO-B Dividends

Yield 12m 0.95%
Yield on Cost 5y 6.19%
Dividends CAGR 5y 11.67%
Payout Consistency 98.2%

NOVO-B Growth Ratios

Growth 12m 83.71%
Growth Correlation 12m 84%
Growth Correlation 3m 58%
CAGR 5y 45.54%
CAGR/Mean DD 5y 10.71
Sharpe Ratio 12m 2.54
Alpha vs SP500 12m 67.05
Beta vs SP500 5y weekly 0.51
ValueRay RSI 63.86
Volatility GJR Garch 1y 24.93%
Price / SMA 50 7.89%
Price / SMA 200 26.55%
Current Volume 4624.5k
Average Volume 20d 2437.7k

External Links for NOVO-B Stock

Tweets
XStocktwits
Fund Manager Positions
DataromaStockcircle
What is the price of NOVO-B stocks?
As of June 22, 2024, the stock is trading at DKK 987.90 with a total of 4,624,522 shares traded.
Over the past week, the price has changed by -0.31%, over one month by +6.55%, over three months by +11.31% and over the past year by +82.90%.
What are the forecast for NOVO-B stock price target?
According to ValueRays Forecast Model, NOVO-B Novo Nordisk A/S will be worth about 1457 in June 2025. The stock is currently trading at 987.90. This means that the stock has a potential upside of +47.49%.
Issuer Forecast Upside
Wallstreet Target Price 929.1 -5.95
Analysts Target Price - -
ValueRay Target Price 1457 47.5

The History of Novo Nordisk A/S

Novo Nordisk A/S, a global healthcare company, has its roots firmly planted in Denmark. Born from the merger of two Danish companies, Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium in 1989, its legacy dates back to the early 20th century, focusing on diabetes care. An enduring commitment to innovation and care has guided its journey, evolving from providing insulin to offering a wide range of healthcare solutions.

Core Business

At its core, Novo Nordisk is dedicated to defeating diabetes. Its broad portfolio of insulin products and diabetes care technologies stands testament to this mission. The company leads in diabetic care, investing heavily in research and development to bring forward new treatment options and insulin analogues to improve the quality of life for people with diabetes.

Side Business Ventures

Beyond diabetes care, Novo Nordisk has diversified into other areas of healthcare. This includes haemophilia treatments, growth hormone therapy, and weight management solutions. Each of these sectors represents a strategic expansion, leveraging their extensive knowledge in biopharmaceuticals to address complex health issues, aiming for a holistic approach to healthcare.

Current Market Status

Today, Novo Nordisk A/S (CO:NOVO-B) maintains a strong presence in the global healthcare market. Its continued focus on innovation, along with a growing demand for diabetes care and obesity treatments, positions the company favorably. Despite the inherent challenges in the sector, including regulatory hurdles and market competition, Novo Nordisk's dedication to addressing chronic diseases keeps it at the forefront of the industry. The company's stock reflects its robust financial health and the trust investors place in its mission and strategic direction.